Parkinson's Disease
NEJM 339:1044-1053,1130-1143, Lang,A.E.&Lozano,A.M., 1998
Parkinsons Disease
NEJM 391:442-452, Tanner,C.M. & Ostrem,J.L., 2024
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Overweight After Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson Disease: Long Term Follow-Up
JNNP 80:484-488, Bannier,S.,et al, 2009
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Early Dopaminergic Drug-Induced Hallucinations in Parkinsonian Patients
Neurol 51:811-814, Goetz,C.G.,et al, 1998
Parkinsonism-Recognition and Differential Diagnosis
BMJ 310:447-452, Quinn,N., 1995
Parkinsonism Caused by Petroleum Waste Ingestion
Neurol 44:1051-1054, Tetrud,J.W.,et al, 1994
Nigral Dysfunction in Drug-Induced Parkinsonism:An F-dopa PET Study
Neurol 43:552-556, Burn,D.J.&Brooks,D.J., 1993
Bilateral Fetal Mesencephalic Grafting in Two Patients with Parkinsonism Induced by MPTP
NEJM 327:1556-1563, 15891992., Widner,H.,et al, 1992
Cyanide-Induced Parkinsonism:Clinical, MRI, and 6-Fluorodopa PET Studies
Neurol 39:142-144, Rosenberg,N.L.,et al, 1989
Locus Ceruleus Lesions & Eosinophilic Inclusions in MPTP-Treated Monkeys
Ann Neurol 20:449-455, Forno,L.S.,et al, 1986
Restless Legs Syndrome, A Review
JAMA 335:703-714, Winkelmen,J.W. & Wipper, B., 2026
A Woman with Parkinson Disease, Dyskinesia, Rhadomyolysis, Subcutaneous Emphysema, and Pneumomediastinum
Neurol 106:e218064, Iqbal,M.M.,et al, 2026
Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Beware of Deep Water After Subthalamic Deep Brain Stimulation
Neurol 94:39-41, Waldvogel, D.,et al, 2020
Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinsons Disease
NEJM 382:1926-1932, Schweitzer, J.S.,et al, 2020
Deep Brain Stimulation in Early-Stage Parkinson Disease
Neurol 95:e393-e401,e431, Hacker, M.L.,et al, 2020
Non-Motor Symptoms in Parkinsons Disease are Reduced by Nabilone
Ann Neurol 88:712-722, Peball, M.,et al, 2020
Randomized Trial of Focused Ultrasound Subthalamotomy for Parkinsons Disease
NEJM 383:2501-2513,2582, Martinez-Fernandez, R.,et al, 2020
Placebo-Controlled, Randomized, Double-Blind Study of IncobotulinumtoxinA for Sialorrhea
Neurol 92:e1982-e1991, Jost, W.H.,et al, 2019
Suicide and Suicide Attempts after Subthalamic Nucleus Stimulation in Parkinson Disease
Neurol 93:e97-e105, Giannini, G.,et al, 2019
MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia?
AJNR 38:1737-1741, Shams, S.,et al, 2017
Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients with Medication-Refractory, Tremor-Dominant Parkinson Disease
JAMA Neurol 74:1412-1418, Bond, A.E.,et al, 2017
Restless Legs Syndrome Associated with Major Diseases
Neurol 86:1336-1343, Trenkwalder, C.,et al, 2016
Distinguishing Neuroimaging Features in Patients Presenting with Visual Hallucinations
AJNR 37:774-781, Winton-Brown, T.T.,et al, 2016
Cystic Lesions as a Rare Complication of Deep Brain Stimulation
Mov Disord Clin Pract 3:87-90, Sharma, V.D.,et al, 2016
Non-Alzheimers Dementia 2 Lewy Body Dementias
Lancet 386:1683-1697, Walker, Z.,et al, 2015
Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Long-Term Safety and Tolerability of ProSavin, a Lentiviral Vector-Based Gene Therapy for Parkinsons Disease: A Dose Escalation, Open-Label, Phase 1/2 Trial
Lancet 383:1138-1146,1107, Palfi, S.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Degenerative Diseases of the Nervous System, Parkinson Disease
Adams & Victors Principles of Neurology, Chp 39, pg 1082, Ropper, A.H.,et al, 2014
Clinical Features of Dopamine Agonist Withdrawal Syndrome in a Movement Disorders Clinic
JNNP 84:130-135, Pondal, M.,et al, 2013
Neurostimulation for Parkinsons Disease with Early Motor Complications
NEJM 368:610-622, Rau, W.,et al, 2013
A Randomized, Double-Blind, Placebo-Controlled Trial of Antidepressants in Parkinson Disease
Neurol 78:1229-1236, Richard,I.H.,et al, 2012
Deep-Brain Stimulation for Parkinsons Disease
NEJM 367:1529-1538, Okon, M.S., 2012
Role of Brain Imaging in Early Parkinsonism
BMJ 324:d638, Breen,D.P.,et al, 2011
Deep Brain Stimulation for Parkinson Disease: An Expert Consensus and Review of Key Issues
Arch Neurol 68:165-171, Bronstein,J.M.,et al, 2011
Patterns and Trends in Antipsychotic Prescribing for Parkinson Disease Psychosis
Arch Neurol 68:899-904, Weintraub, D.,et al, 2011
Diagnosis and Treatment of Psychogenic Parkinsonism
JNNP 82:1300-1303, Jankovic, J., 2011
Neuropathy in Parkinson Disease
Neurol 77:1947-1950, e132, Rajabally, Y.A. and Martey, J., 2011
Dopamine Agonist Withdrawal Syndrome in Parkinson Disease
Arch Neurol 67:58-63, Rabinak,C. &Nirenberg,M., 2010
(-Synuclein Accumulation in Skin Nerve Fibers Revealed by Skin Biopsy in Pure Autonomic Failure
Neurol 74:608-610,536, Shishido,T.,et al, 2010
Bilateral Deep Brain Stimulation vs Best Medical Therapy for Patients with Advanced Parkinson Disease: A Randomized Controlled Trial
JAMA 301:63-73,104, Weaver,F.M.,et al, 2009
Long-Term Effect of Initiating Pramipexole vs Levodopa in Early Parkinson Disease
Arch Neurol 66:563-570, Parkinson Sutdy Group CALM Cohort Investigators, 2009
Road Safety in Drivers With Parkinson Disease
Neurol 73:2112-2119, Uc,E.,et al, 2009
Statin Use and the Risk of Parkinson Disease
Neurol 70:1418-1422, Wahner,A.D.,et al, 2008
Use of Antihypertensives and the Risk of Parkinson Disease
Neurol 70:1438-1444, Becker,C.,et al, 2008